JDOC JPMorgan Healthcare Leaders ETF
ETF on NASDAQ (US) · Actively managed · Listing
Changes appear once four weeks of holdings are on file.
Largest holding: Eli Lilly and Company, 613 shares ($868K).
| Current positions Top 10 | % of book |
|---|---|
| Eli Lilly and Company LLY $868K | 8.8% |
| AbbVie Inc. ABBV $837K | 8.5% |
| UnitedHealth Group Incorporated UNH $512K | 5.2% |
| Johnson & Johnson JNJ $471K | 4.8% |
| NOVARTIS AG COMMON STOCK NOVN $451K | 4.6% |
| Thermo Fisher Scientific Inc TMO $427K | 4.3% |
| ASTRAZENECA PLC COMMON AZN $406K | 4.1% |
| Merck & Company, Inc. MRK $345K | 3.5% |
| Danaher Corporation DHR $276K | 2.8% |
| Intuitive Surgical, Inc. ISRG $254K | 2.6% |
Slices are % of holdings value.
| Sectors | % of long value |
|---|---|
| Healthcare | 73.8% |
| Unclassified | 26.2% |
| Industries | % of long value |
|---|---|
| Drug Manufacturers - General | 27.6% |
| Biotechnology | 13.7% |
| Medical Devices | 10.0% |
| Healthcare Plans | 8.6% |
| Medical Instruments & Supplies | 4.3% |
| Medical Distribution | 3.8% |
| Health Information Services | 2.0% |
| Other (3) | 3.8% |
| Unclassified | 26.2% |
Source: the fund's own published holdings, the portfolio of Nov 17, 2026 (am.jpmorgan.com). Cash and money-market lines are in the book and its value but are never counted as trades. Short positions are listed as such, at their (negative) printed value.
Objective
From the summary prospectus filed Feb 25, 2026.
The Fund seeks to provide long-term capital appreciation.
Principal investment strategies
The Fund will invest primarily in equity securities issued by pharmaceutical, biotechnology, healthcare services, healthcare technology, medical technology and life sciences companies (Healthcare Companies) which the adviser believes are leaders and where the magnitude and/or duration of future growth for these companies is underappreciated by the market. The Fund will invest in common stocks of Healthcare Companies across all market capitalizations, but expects to invest a majority of its assets in mid- and large- capitalization companies. The Fund will invest globally, including in both developed and emerging market countries, although it expects to invest a majority of its Assets in Healthcare Companies located in the U.S. Prior to June 1, 2026, under normal circumstances, the Fund invests at least 80% of its Assets in the equity securities of Healthcare Companies. The adviser determines that a security is generally appropriate for the Fund if at least 50% of the issuer's assets, revenues, or net income is related to, or derived from, the group of industries in the healthcare sector. "Assets" means net assets, plus the amount of any borrowings for investment purposes. Effective June 1, 2026, under normal circumstances, the Fund will invest at least 80% of its Assets in the equity securities of Healthcare Companies that the adviser considers to be leaders. The adviser determines that a security is generally appropriate for the Fund if at least 50% of the issuer's assets, revenues, or net income is related to, or derived from, the group of industries in the healthcare sector. In addition, leaders are those that the adviser believes are above median compared to Healthcare Companies, based on one or more of the following attributes: revenue growth, free cash flow growth, earnings per share growth, free cash flow margin and operating margin, all of which may be considered on a projected or a historic basis. "Assets" means net assets, plus the amount of any borrowings for investment purposes. 1 The Fund's equity securities may include common stock and depositary receipts. Depositary receipts are financial instruments representing a foreign company's publicly traded securities. A depository receipt trades on a stock exchange in a country different from the company's local market. Derivatives, which are instruments that have a value based on another instrument, exchange rate or index, may be used as substitutes for securities in which the Fund can invest. The Fund may use options, futures and other derivatives for risk management purposes and to provide equity market exposure. For example, the Fund may use exchange-traded futures to gain exposure to particular securities or markets and for the efficient management of cash flows. In addition, the Fund may invest in securities denominated in any currency and may from time to time hedge a portion of its foreign currency exposure using currency forwards. The Fund has a fundamental policy to concentrate its investments in a group of industries in the healthcare sector. This means that the Fund will invest 25% or more of its total assets across a group of industries in the healthcare sector. Investment Process: The Fund seeks to take advantage of the upside potential in the healthcare sector by investing in Healthcare Companies that the adviser believes the market underappreciates. In choosing securities to purchase, the adviser internally evaluates issuers to identify those that, in the adviser's view, are leaders in the healthcare sector. The adviser leverages its proprietary research capabilities to identify these companies, with coverage provided by a team of dedicated healthcare specialists located around the world. Healthcare Companies that the adviser believes are "leaders" include those that have "catalysts" that the adviser believes will lead them to outperform their peers.
Management and Contact
- Adviser
- J.P. Morgan Investment Management Inc.
- Portfolio managers
-
Dominic Valder (since 2023, Executive Director);
Bartjan van Hulten (since 2024, Managing Director)
- Phone
- 1-844-457-6383
- [email protected]
Track Record as of Dec 31, 2025
Average annual total returns from the summary prospectus. Returns in percent; periods over a year are annualized.
| 1 Year | Since Inception | |
|---|---|---|
| Return Before Taxes | 14.94% | 12.23% |
| Return After Taxes on Distributions | 14.70% | 11.11% |
| Return After Taxes on Distributions and Sale of Fund Shares | 9.02% | 9.05% |
| MSCI WORLD HEALTH CARE INDEX (Net Total Return) (Reflects No Deduction for Fees, Expenses, or Taxes, Except Foreign Withholding | 14.83% | 12.16% |
| MSCI WORLD INDEX (Net Total Return) (Reflects No Deduction for Fees, Expenses, or Taxes, Except Foreign Withholding Taxes) | 21.09% | 25.96% |
Holdings as of Nov 17, 2026
The full portfolio the fund publishes every business day on its website (am.jpmorgan.com). Every line is listed: holdings we could identify link to their page, the rest (cash, options, swaps, private shares, securities we do not carry) are shown as the fund prints them. Short positions are negative. Change is the share count against Nov 16, 2026.
61 lines, 38 linked, weights sum to 99.96% · Actively managed (N-CEN)
| Holding | Ticker / identifier | Type | Shares | Change | Weight | Market value |
|---|---|---|---|---|---|---|
| ELI LILLY AND COMPANY | LLY | Equity | 613 | 0 | 8.78% | $ 867.732K |
| ABBVIE INC COMMON STOCK | ABBV | Equity | 2,858 | 0 | 8.47% | $ 836.88K |
| UNITEDHEALTH GROUP INC | UNH | Equity | 1,313 | 0 | 5.18% | $ 511.65K |
| JOHNSON & JOHNSON COMMON | JNJ | Equity | 1,689 | 0 | 4.76% | $ 470.724K |
|
NOVARTIS AG COMMON STOCK
|
NOVN | Equity | 2,840 | 0 | 4.56% | $ 450.598K |
| THERMO FISHER SCIENTIFIC | TMO | Equity | 622 | 0 | 4.32% | $ 427.183K |
|
ASTRAZENECA PLC COMMON
|
AZN | Equity | 2,233 | 0 | 4.11% | $ 406.041K |
| MERCK & CO INC COMMON | MRK | Equity | 2,407 | 0 | 3.49% | $ 345.092K |
| DANAHER CORP COMMON STOCK | DHR | Equity | 1,223 | 0 | 2.79% | $ 276.117K |
| INTUITIVE SURGICAL INC | ISRG | Equity | 590 | 0 | 2.57% | $ 254.013K |
|
NOVO NORDISK A/S COMMON
|
NOVO-B | Equity | 6,019 | 0 | 2.48% | $ 245.092K |
| CENCORA INC COMMON STOCK | COR | Equity | 663 | 0 | 2.35% | $ 232.421K |
| STRYKER CORP COMMON STOCK | SYK | Equity | 671 | 0 | 2.16% | $ 213.069K |
| BRISTOL-MYERS SQUIBB CO | BMY | Equity | 3,342 | 0 | 2.07% | $ 205.032K |
| REGENERON PHARMACEUTICALS | REGN | Equity | 213 | 0 | 2.06% | $ 204.003K |
| IQVIA HOLDINGS INC COMMON | IQV | Equity | 777 | 0 | 2.03% | $ 200.155K |
|
TAKEDA PHARMACEUTICAL CO
|
4502 | Equity | 4,600 | 0 | 2.02% | $ 199.977K |
| HUMANA INC COMMON STOCK | HUM | Equity | 441 | 0 | 1.98% | $ 195.513K |
| EDWARDS LIFESCIENCES CORP | EW | Equity | 1,827 | 0 | 1.95% | $ 192.621K |
|
ARGENX SE COMMON STOCK
|
ARGX | Equity | 201 | +186 | 1.92% | $ 189.557K |
|
ROCHE HOLDING AG COMMON
|
ROP | Equity | 377 | 0 | 1.84% | $ 181.829K |
|
BAYER AG COMMON STOCK EUR
|
BAYN | Equity | 2,707 | 0 | 1.69% | $ 167.063K |
| BIOGEN INC COMMON STOCK | BIIB | Equity | 663 | 0 | 1.68% | $ 166.274K |
| VERTEX PHARMACEUTICALS | VRTX | Equity | 299 | 0 | 1.62% | $ 159.726K |
| HCA HEALTHCARE INC COMMON | HCA | Equity | 305 | 0 | 1.55% | $ 152.863K |
|
GENMAB A/S
|
GMAB | Equity | 295 | 0 | 1.54% | $ 152.412K |
| CARDINAL HEALTH INC | CAH | Equity | 521 | 0 | 1.47% | $ 145.489K |
|
TEVA PHARMACEUTICAL
|
TEVA | Equity | 3,445 | 0 | 1.46% | $ 143.987K |
| CENTENE CORP COMMON STOCK | CNC | Equity | 1,935 | 0 | 1.42% | $ 140.384K |
|
SANDOZ GROUP AG COMMON
|
SDZ | Equity | 1,359 | 0 | 1.36% | $ 134.164K |
| ZOETIS INC COMMON STOCK | ZTS | Equity | 1,541 | 0 | 1.30% | $ 128.643K |
|
FRESENIUS SE & CO KGAA
|
FRE | Equity | 1,831 | 0 | 1.09% | $ 108.171K |
| ZIMMER BIOMET HOLDINGS | ZBH | Equity | 981 | 0 | 1.01% | $ 100.15K |
| CHARLES RIVER | CRL | Equity | 289 | 0 | 0.97% | $ 95.994K |
|
CASH
|
Cash | 93,373 | 0 | 0.94% | $ 93.373K | |
| NEUROCRINE BIOSCIENCES | NBIX | Equity | 540 | 0 | 0.91% | $ 89.597K |
| ABBOTT LABORATORIES | ABT | Equity | 803 | 0 | 0.85% | $ 84.082K |
| REVOLUTION MEDICINES INC | RVMD | Equity | 469 | 0 | 0.77% | $ 76.302K |
| DISC MEDICINE INC COMMON | IRON | Equity | 891 | 0 | 0.69% | $ 68.224K |
| MEDTRONIC PLC COMMON | MDT | Equity | 622 | 0 | 0.64% | $ 63.643K |
| BRIDGEBIO PHARMA INC | BBIO | Equity | 822 | 0 | 0.64% | $ 63.13K |
|
CONVATEC GROUP PLC COMMON
|
CTEC | Equity | 18,179 | 0 | 0.60% | $ 59.136K |
| PTC THERAPEUTICS INC | PTCT | Equity | 790 | 0 | 0.48% | $ 47.684K |
| DYNE THERAPEUTICS INC | DYN | Equity | 2,968 | 0 | 0.48% | $ 47.547K |
| SPYRE THERAPEUTICS INC | SYRE | Equity | 492 | 0 | 0.47% | $ 46.155K |
| ALIGN TECHNOLOGY INC | ALGN | Equity | 271 | 0 | 0.45% | $ 44.298K |
| LB PHARMACEUTICALS INC | LBRX | Equity | 1,059 | 0 | 0.43% | $ 42.678K |
| BOSTON SCIENTIFIC CORP | BSX | Equity | 792 | 0 | 0.34% | $ 34.08K |
|
JPMORGAN U.S. GOVERNMENT
|
MGMXX | Money market | 27,466 | 0 | 0.28% | $ 27.466K |
| LEGEND BIOTECH CORP ADR | LEGN | Equity | 1,539 | 0 | 0.25% | $ 24.793K |
| APNIMED INC COMMON STOCK | APMD | Equity | 1,276 | 0 | 0.23% | $ 22.713K |
| INSMED INC COMMON STOCK | INSM | Equity | 127 | 0 | 0.16% | $ 15.476K |
|
ARGENX SE
|
ARGX | Equity | 15 | 0 | 0.14% | $ 14.146K |
|
GSK PLC COMMON STOCK GBP
|
GSK | Equity | 521 | 0 | 0.13% | $ 12.822K |
|
ISRAELI SHEKEL
|
Other | 6,479 | 0 | 0.02% | $ 1,991.99 | |
|
SWISS FRANC
|
Cash | 1,103 | +1,103 | 0.01% | $ 1,313.21 | |
|
SARTORIUS AG PREFERENCE
|
SRT3 | Equity | 1 | 0 | 0.00% | $ 320.41 |
|
DANISH KRONE
|
Other | 0 | 0 | 0.00% | $ 0.00 | |
|
JAPANESE YEN
|
Cash short | -3 | 0 | 0.00% | $ -0.02 | |
|
BRITISH POUND
|
Cash | 0 | 0 | 0.00% | $ -0.25 | |
|
EURO
|
Cash | 0 | 0 | 0.00% | $ -0.66 |
Trades Nov 16, 2026 to Nov 17, 2026
Changes in shares between the fund's two newest published portfolios, cash left out. Value is the change at the line's own price in the newer portfolio.
| Holding | Ticker | Action | Before | After | Change | Value |
|---|
Podcast Mentions
Sign up to see podcast mentions and sentiment
Sign Up